MARKET

APGE

APGE

Apogee Therapeutics Inc
NASDAQ
132.91
+0.14
+0.11%
After Hours: 132.91 0 0.00% 17:39 07/02 EDT
OPEN
133.60
PREV CLOSE
132.77
HIGH
133.85
LOW
132.73
VOLUME
3.00M
TURNOVER
--
52 WEEK HIGH
133.85
52 WEEK LOW
34.34
MARKET CAP
9.99B
P/E (TTM)
-30.6852
1D
5D
1M
3M
1Y
5Y
1D
Apogee Therapeutics CMO Carl Dambkowski sells 5,500 common shares worth $730,070
PUBT · 1d ago
XBI, APGE, KYMR, TWST: Large Inflows Detected at ETF
NASDAQ · 2d ago
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?
NASDAQ · 4d ago
U.S. Equity Markets: Lots Of Gambling Going On
Seeking Alpha · 4d ago
Biotech Is The Rate Cut Trade In Disguise
Seeking Alpha · 5d ago
Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It
Seeking Alpha · 5d ago
Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
NASDAQ · 5d ago
Weekly Report: what happened at APGE last week (0622-0626)?
Weekly Report · 5d ago
More
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.

Webull offers Apogee Therapeutics Inc stock information, including NASDAQ: APGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APGE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APGE stock methods without spending real money on the virtual paper trading platform.